Abstract
Objectives
To describe changes in hemodynamics, respiratory support, and growth associated with transcatheter PDA closure (TCPC) in ELBW infants, stratified by postnatal age at treatment.
Study design
This is an observational study of ELBW infants who underwent TCPC at ≤4 weeks (Group-1; n = 34), 4–8 weeks (Group-2; n = 33), and >8 weeks of age (Group-3; n = 33). Hemodynamic assessment was performed during TCPC. Multivariate Cox-proportionate-hazard modeling was used to identify factors associated with respiratory severity score (RSS) > 2 for >30 days following TCPC.
Results
In comparison with Group-1, Group-3 infants had higher pulmonary vascular resistance (PVRi = 3.3 vs. 1.6 WU*m2; P = 0.01), less weight gain between 4 and 8 weeks of age (16 vs. 25 g/day) and took longer to achieve RSS < 2 (median 81 vs. 20 days; P = 0.001). RSS > 2 for >30 days was associated with TCPC > 8 weeks (OR = 3.2, 95% CI: 1.75–5.8; p = 0.03) and PVRi ≥ 3 (OR = 4.5, 95% CI: 2.7–8.9; p < 0.01).
Conclusion
ELBW infants may benefit from PDA closure within the first 4 weeks of life in order to prevent early onset pulmonary vascular disease, promote faster growth, and for quicker weaning of ventilator and oxygen support.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123:e138–44.
Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30:241–52.
Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, et al. An exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41–8.
Benitz WE. Committee on fetus and newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016;137:e20153730.
Benitz WE, Bhombal S. The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants. Semin Fetal Neonatal Med. 2017;22:302–7.
Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, et al. Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). J Perinatol. 2019;39:599–607.
Shelton EL, Waleh N, Plosa EJ, Benjamin JT, Milne GL, Hooper CW, et al. Effects of antenatal betamethasone on preterm human and mouse ductus arteriosus: comparison with baboon data. Pediatr Res. 2018;84:458–65.
Clyman R, Cassady G, Kirklin JK, Collins M, Philips JB III. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr. 2009;154:873–6.
Sung SI, Chang YS, Chun JY, Yoon SA, Yoo HS, Ahn SY, et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr. 2016;177:66–71.
Philip R, Waller BR 3rd, Agrawal V, Wright D, Arevalo A, Zurakowski D, et al. Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device. Catheter Cardiovasc Inter. 2016;87:310–7.
Sathanandam S, Balduf K, Chilakala S, Washington K, Allen K, Knott-Craig C, et al. Role of transcatheter patent ductus arteriosus closure in extremely low birth weight infants. Catheter Cardiovasc Inter. 2019;93:89–96.
Sathanandam S, Agrawal H, Chilakala S, Johnson J, Allen K, Knott-Craig C, et al. Can Transcatheter PDA closure be performed in neonates ≤1000 grams? The Memphis experience. Congenit Heart Dis. 2019;14:79–84.
Agrawal H, Waller BR 3rd, Surendan S, Sathanandam S. New patent ductus arteriosus closure devices and techniques. Inter Cardiol Clin. 2019;8:23–32.
Sathanandam S, Justino H, Waller BR 3rd, Radtke W, Qureshi AM. Initial clinical experience with the Medtronic Micro Vascular Plug™ in transcatheter occlusion of PDAs in extremely premature infants. Catheter Cardiovasc Inter. 2017;89:1051–8.
Johnson JN, Sathanandam S, Naik R, Philip R. Echocardiographic guidance for transcatheter patent ductus arteriosus closure in extremely low birth weight infants. Congenit Heart Dis. 2019;14:74–8.
McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007;92:F424–7.
Alexander J, Yohannan T, Abutineh I, Agrawal V, Lloyd H, Zurakowski D, et al. Ultrasound guided femoral arterial access in pediatric cardiac catheterizations: a prospective evaluation of the prevalence, risk factors, and mechanism for acute loss of arterial pulse. Catheter Cardiovasc Inter. 2016;88:1098–107.
Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037–99.
Niu MC, Mallory GB, Justino H, Ruiz FE, Petit CJ. Treatment of severe pulmonary hypertension in the setting of the large patent ductus arteriosus. Pediatrics. 2013;131:e1643–9.
Yan C, Zhao S, Jiang S, Xu Z, Huang L, Zheng H, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007;93:514–8.
Feng J, Kong X, Sheng Y, Yang R. Patent ductus arteriosus with persistent pulmonary artery hypertension after transcatheter closure. Ther Clin Risk Manag. 2016;12:1609–13.
Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol. 2011;31:635–40.
Sathanandam S, Whiting S, Cunningham J, Zurakowski D, Apalodimas L, Waller BR, et al. Practice variation in the management of patent ductus arteriosus in extremely low birth weight infants in the United States: survey results among cardiologists and neonatologists. Congenit Heart Dis. 2019;14:6–14.
Bixler GM, Powers GC, Clark RH, Walker MW, Tolia VN. Changes in the diagnosis and management of patent ductus arteriosus from 2006 to 2015 in United States Neonatal Intensive Care Units. J Pediatr. 2017;189:105–12.
Benitz WE. Hey, doctor, leave the PDA alone. Pediatrics. 2017;140:e20170566.
Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. 2014;164:510–4.
Zecca E, Romagnoli C, De Carolis MP, Costa S, Marra R, De Luca D. Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics. 2009;124:480–4.
Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007;119:1165–74. 28
Mirea L, Sankaran K, Seshia M, Ohlsson A, Allen AC, Aziz K, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr. 2012;161:689–94.
Clyman RI, Benitz WE. Transcatheter patent ductus arteriosus closure-will history repeat itself? J Perinatol. 2019;39:1435–6.
Apalodimas L, Waller IIIBR, Philip R, Crawford J, Cunningham J, Sathanandam S. A comprehensive program for preterm infants with patent ductus arteriosus. Congenit Heart Dis. 2019;14:90–4.
Liebowitz M, Clyman RI. Prophylactic indomethacin compared with delayed conservative management of the patent ductus arteriousus in extremely preterm infants: effects on neonatal outcomes. J Pediatr. 2017;187:119–26.
Liebowitz M, Fonseca E, Georgiev SG, Gorenflo M, Loukanov TS. Patent ductus arteriosus in preterm infants: benefits of early surgical closure. Asian Cardiovasc Thorac Ann. 2014;22:391–6.
Sathanandam SK, Gutfinger D, O’Brien L, Forbes TJ, Gillespie MJ, Berman DP, et al. Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams. Catheter Cardiovasc Interv. 2020. https://doi.org/10.1002/ccd.28973. [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Philip, R., Waller, B.R., Chilakala, S. et al. Hemodynamic and clinical consequences of early versus delayed closure of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 41, 100–108 (2021). https://doi.org/10.1038/s41372-020-00772-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-020-00772-2
This article is cited by
-
PDA management strategies and pulmonary hypertension in extreme preterm infants with bronchopulmonary dysplasia
Pediatric Research (2024)
-
3-year follow-up of a prospective, multicenter study of the Amplatzer Piccolo™ Occluder for transcatheter patent ductus arteriosus closure in children ≥ 700 grams
Journal of Perinatology (2023)
-
Phenotyping respiratory decompensation following definitive closure of the patent ductus arteriosus in preterm infants
Journal of Perinatology (2022)
-
Consensus Guidelines for the Prevention and Management of Periprocedural Complications of Transcatheter Patent Ductus Arteriosus Closure with the Amplatzer Piccolo Occluder in Extremely Low Birth Weight Infants
Pediatric Cardiology (2021)